Form 4: Organon Interim CEO's Stock Transactions

Organon & Co.'s Interim CEO, Joseph T. Morrissey Jr., reported the acquisition and disposition of common stock related to performance share unit vesting and dividend equivalents.

Summary

• Joseph T. Morrissey Jr., Interim CEO of Organon & Co. (OGN), reported transactions involving the company's common stock.
• On February 27, 2026, Morrissey acquired 27,564 shares of common stock at a price of $0, stemming from the release of performance share units (PSUs) granted on August 11, 2023.
• The performance-vesting restrictions for these PSUs were released after the Talent Committee of Organon's Board of Directors certified the attainment of performance goals.
• Additionally, Morrissey acquired 7,777 shares of common stock at $0, representing dividend equivalents earned on the released PSUs.
• To cover tax withholding obligations, Morrissey disposed of 8,054 shares at $7.17 and 2,216 shares at $7.23 on the same date.
• Following these transactions, Morrissey's direct beneficial ownership of Organon & Co. common stock stands at 98,570.923 shares.
• The reported beneficial ownership also includes an additional 1,938.068 shares acquired from dividend equivalents net of withholding tax, which were not previously required to be reported.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as the vesting of performance share units indicates the company met its performance goals, reflecting positively on management's execution and aligning the Interim CEO's interests with shareholders.

Positives

• The vesting of 27,564 performance share units indicates that Organon & Co. met specific performance goals, as certified by the Board's Talent Committee.
• The acquisition of 7,777 shares from dividend equivalents demonstrates the company's dividend policy and the accumulation of value for equity holders.
• The increase in overall beneficial ownership (even after tax-related dispositions) for the Interim CEO aligns management's interests with shareholders.

Negatives

• The disposition of 8,054 shares at $7.17 and 2,216 shares at $7.23 were for tax withholding purposes, which is a routine event for equity compensation vesting and not a discretionary sale by the insider.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the vesting of performance-based equity awards and subsequent tax-related dispositions, are common across the pharmaceutical and biotechnology sectors. These events reflect standard executive compensation practices tied to company performance.

Comparison to Industry Standards

• The structure of performance share units (PSUs) tied to performance goal attainment is a widely adopted practice in executive compensation across large-cap pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson.
• These companies frequently use such long-term incentives to align executive interests with shareholder value creation.
• The specific performance goals are not detailed in this filing, but the certification by the Talent Committee suggests adherence to established corporate governance practices.

Corporate Governance

Related Party Transactions

• The transactions involve equity compensation (Performance Share Units and dividend equivalents) granted by Organon & Co. to its Interim CEO, Joseph T. Morrissey Jr., which are considered related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The vesting of PSUs suggests positive company performance, potentially increasing confidence in management. The increase in the Interim CEO's beneficial ownership aligns his interests with shareholders.
• Employees: The successful vesting of performance-based awards can signal a healthy company performance culture.

Key Dates

Keywords

Organon & Co., OGN, Joseph T. Morrissey Jr., Interim CEO, insider transaction, Form 4, common stock, performance share units, PSUs, equity compensation, dividend equivalents, beneficial ownership